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ABSTRACT 
Aberrant changes in microRNA expression contribute to lymphomagenesis. Bromodomain and extra-
terminal domain inhibitors like OTX015 (MK-8628, birabresib) have demonstrated preclinical and 
clinical activity in haematological tumours. MicroRNA profiling of diffuse large B-cell lymphoma cells 
treated with OTX015 revealed changes in the expression levels of a limited number of microRNAs, 
including miR-92a-1-5p, miR-21-3p, miR-155-5p and miR-96-5p. Analysis of publicly available ChIP-
Seq data of diffuse large B-cell lymphoma cells treated with bromodomain and extra-terminal domain 
(BET) inhibitors showed that the BET family member BRD4 bound to the upstream regulatory regions 
of multiple microRNA genes and that this binding decreased following BET inhibition. Alignment of our 
microRNA profiling data with the BRD4 ChIP-Seq data revealed that microRNAs downregulated by 
OTX015 also exhibited reduced BRD4 binding in their promoter regions following treatment with 
another bromodomain and extra-terminal domain inhibitor, JQ1, indicating that BRD4 directly 
contributes to microRNA expression in lymphoma. Treatment with bromodomain and extra-terminal 
domain inhibitors also decreased the expression of the arginine methyltransferase PRMT5, which 
plays a crucial role in B-cell transformation and negatively modulates the transcription of miR-96-5p.  
The data presented here indicate that in addition to the previously observed effects on the expression 
of coding genes, bromodomain and extra-terminal domain inhibitors also modulate the expression of 
microRNAs involved in lymphomagenesis. 
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INTRODUCTION 
The important role of noncoding elements of the genome, specifically microRNAs (miRNA), in 
mediating cellular transformation was first demonstrated in chronic lymphocytic leukaemia 1.  Since 
then, numerous miRNAs have been shown to function as tumour suppressors or oncogenes in both 
haematological and solid tumours 2-8. miRNAs are short sequences of 19 – 25 nucleotides that 
function as part of an RNA-induced silencing complex (RISC) 9. In humans, they function primarily by 
destabilizing messenger RNA (mRNA) and inhibiting the translation of mRNA into protein. This is 
achieved through binding of the 5’ seed region of a miRNA to its recognition sequence in the 3’ 
untranslated (3’ UTR) of its target gene 10. A single miRNA can recognise multiple target genes and 
conversely, different miRNAs can target an individual gene 11. Thus, in the context of cancer, miRNAs 
can intricately and markedly influence individual driver genes and entire signalling pathways crucial to 
the survival of cancer cells. Furthermore, a number of miRNAs have been shown to participate in a 
feedback loop with the protein product of their target gene 11.  
Diffuse large B cell lymphoma (DLBCL) is an aggressive lymphoma that accounts for approximately 
35-40% of all lymphoma cases 12. DLBCLs frequently harbour mutations in chromatin modifying 
enzymes indicating that perturbation of epigenetic regulation is an important trigger for B cell 
transformation 13, 14. A class of epigenetic drugs that has recently shown promising results in pre-
clinical and clinical settings, and particularly in DLBCL, inhibit members of the bromodomain and 
extra-terminal domain (BET) protein family 15-25. In mammals, the BET family comprises four proteins, 
BRD2, BRD3, BRD4 and BRDT, which all share two highly conserved N-terminal bromodomains 
(BRD) and a C-terminal extra-terminal (ET) domain. BET proteins specifically bind to acetylated lysine 
residues via their dual BRD motifs, acting as epigenetic readers of acetyl-lysine marks. They therefore 
constitute an important component of the write-read-erase model via which epigenetic information is 
interpreted by cells 17. BET inhibitors (BETi) act by preventing the interaction of BRD4 with acetylated 
histones 26. Here, we show a direct and indirect regulation of miRNA expression in DLBCL by a BET 
inhibitor. 
 
METHODS 
Cell lines and molecules 
Established human cell lines derived from DLBCL were cultured according to the recommended 
conditions. Two germinal-center B-cell type DLBCL (GCB-DLBCL) cell lines, DOHH-2 and OCI-LY-1, 
were cultured in RPMI and IMDM, respectively. The activated B-cell–like DLBCL (ABC-DLBCL) cell 
lines SU-DHL-2 and HBL-1 were cultured in RPMI. Cell lines were obtained as previously described 27, 
and their identity was authenticated by short tandem repeat (STR) DNA profiling (IDEXX BioResearch, 
Ludwigsburg, Germany). All media were supplemented with foetal bovine serum (10%; DOHH-2 and 
OCI-LY-1 or 20%; SU-DHL-2 and HBL-1), penicillin-streptomycin-neomycin (5,000 units penicillin, 5 
mg streptomycin and 10 mg neomycin/mL, Sigma) and L-glutamine (1%). OTX015 (MK-8628, 
birabresib) was provided by Oncoethix (Lausanne, Switzerland). 
 
In vivo xenograft model 
The xenograft model used here is from a previous publication and has already been described 15. 
Total RNA, previously extracted from these tumours, was used to analyse OTX015-mediated 
modulation of miRNA expression in vivo. 
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Western blotting analysis 
Protein extractions, SDS-PAGE and immunoblotting were performed as previously described 15. The 
antibodies used were: anti-PRMT5 (A1520; NeoBiolab), anti-GAPDH (9131; Cell Signaling) and anti-
BRD4 (A301-985A; Bethyl). 
 
One-step quantitative reverse transcription - polymerase chain reaction (qRT-PCR)  
Total RNA was extracted from DMSO and OTX015-treated cells using TRIzol (Thermo Scientific, 
Lausanne, Switzerland). One-step quantitative reverse transcription - polymerase chain reaction (qRT-
PCR) was performed as previously described 15 using 20 ng of RNA for each reaction. Forward and 
reverse primers used for quantification of PRMT5 mRNA were, respectively: 5’-
TCTCATGGTTTCCCATCCTC-3’ and 5’-ACACAGATGGTTTGGCCTTC-3’. Quantification of GAPDH 
expression served as an endogenous control. GAPDH primer sequences were: 5’-
CGACCACTTTGTCAAGCTCA-3’ (forward) and 5’-CCCTGTTGCTGTAGCCAAAT-3’ (reverse). 
Expression of GAPDH was verified to be stable between the analysed groups. 
 
miRNA expression profiling 
Total RNA was extracted as previously described 15. miRNA expression profiling was performed on 
RNA from DLBCL cell lines treated with DMSO or OTX015 using the Agilent Human microRNA 
microarray v.3 or the Nanostring nCounter Human V3A miRNA Expression Assay Kits. Profiling was 
done on RNA extracted from untreated lymphoma cell lines 27, 28 using the Nanostring nCounter 
Human V2. All samples were processed as previously described 29, 30.  Profiling data are available at 
the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geo) database under the GEO project number GSE99208. 
 
miRNA quantification with TaqMan MicroRNA Assays 
Validation of miRNA profiling results was performed for selected miRNAs using the following TaqMan 
MicroRNA Assays (Applied Biosystems): hsa-miR-96-5p, assay ID: 000186; hsa-miR-92a-1-5p, assay 
ID: 002137, hsa-miR-21-3p, assay ID: 002438; hsa-miR-155-5p, assay ID: 002623; RNU6B, assay ID: 
001093. Reverse transcription and quantitative PCR were performed using the TaqMan MicroRNA 
Reverse Transcription Kit and the TaqMan Universal PCR Master Mix according to the manufacturer’s 
instructions. Briefly, for each sample, 10 ng of total RNA was used for reverse transcription (RT) and 
1.33 μL of RT product was used in triplicate wells for the quantitative PCR (qPCR). All qPCR reactions 
were performed on an Applied Biosystems StepOnePlus System. Amplification of RNU6B served as a 
normalising control for RNA quantity. Data were analysed using the ΔΔCt method to obtain relative 
quantities (RQ). Expression of RNU6B was verified as stable between the analysed groups. 
 
Data mining 
miRNA expression data obtained from each profiling platform was analysed independently. For Agilent 
arrays, the hybridization signal values for the multiple probes were obtained using the Agilent Feature 
Extraction Software 10.7.3 (Agilent Technologies). For the Nanostring nCounter, raw expression data 
were log-transformed and normalized by the quantile method after application of manufacturer-
supplied correction factors. For both platforms, differentially expressed miRNAs were defined using 
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R/Bioconductor with the linear model for microarray data analysis (limma) with a contrast matrix for the 
comparisons of interest on the datasets filtered to exclude features below the detection threshold 
(defined for each sample by a cut-off corresponding to twice the standard deviation of negative control 
probes plus the means) in at least half of the samples. The transcripts bearing an absolute log fold 
change above 0.2 and a p-value below 0.05 at any experimental time point were defined as 
differentially expressed. Overlapping among lists was made using the VENNY on-line tool 31. 
Experimentally validated transcript targets of the miRNAs were obtained using the MicroRNA Target 
Filter in Ingenuity Pathway Analysis (IPA) (Qiagen). Functional annotation of the targets was 
performed using the Gene Set Enrichment Analysis (GSEA) tool for overlap analysis using the 
hallmarks and the c2.cp of the Molecular Signatures Database (MSigDB) 5.2 32 and hypergeometric p-
value after correction for multiple hypothesis testing according to Benjamini and Hochberg < 0.05. 
Publicly available ChIP-Seq datasets obtained by Chromatin Immunoprecipitation (ChIP) followed by 
high-throughput DNA sequencing (ChIP-Seq) were downloaded and re-analysed. They comprised 
datasets obtained in the ABC-DLBCL cell line HBL-1 (SRP043524) 23 and in the GCB-DLBCL cell line 
OCI-LY-1 (SRP022129) 22, both treated with the BET inhibitor JQ1 or DMSO alone. Sequence reads 
obtained from ChIP fragments were aligned to human reference genome hg19 using Bowtie, allowing 
up to one mismatch per fragment length. Redundant reads were removed and only reads uniquely 
mapping to the reference genome were used for further analysis. The detection of peaks that are 
genomic regions enriched by ChIP, relative to the background reads, was carried out using HOMER 
(v2.6), a suite of tools for Motif Discovery and next-generation sequencing analysis, with a default 
option (FDR = 0.001 and Poisson p-value cut-off = 1e-04). Differential peaks were defined as having 
at least a four-fold difference in enrichment within a 200 bp region between the two conditions (DMSO 
versus JQ1) and a Poisson enrichment p-value less than 1e-04. All discovered putative peaks were 
ranked by their Normalized Tag Counts (number of tags found at the peak, normalized to 10 million 
total mapped tags) and annotated with annotatePeaks.pl subroutine. We defined miRNA promoters 
using FANTOM5 33 and the precursors of microRNAs downloaded from miRBase (v20) 34 to annotate 
the BRD4 ChIP-Seq datasets. We defined enriched regions located within 5kb regions of predicted 
promoters and pre-miRNAs as candidate BRD4 binding sites. For global ChIP-Seq visualization, we 
used ngs.plot (https://code.google.com/p/ngsplot/) for inspection of both average and ‘laid out’ 
coverages as curves or heatmaps.  
 
Chromatin Immunoprecipitation 
Cells (SU-DHL-2 and HBL-1) were cross-linked with 1% formaldehyde. Crosslinking was quenched 
with 125 mM glycine. Cells were washed with ice-cold PBS containing 1 X HALT protease inhibitor 
(Thermo Scientific, Lausanne, Switzerland) and resuspended in SDS lysis buffer (ChIP Assay Kit, 
Millipore, Schaffhausen, Switzerland) before sonication using the Bioruptor Plus. For each 
immunoprecipitation reaction, chromatin from 1 X 106 cells was incubated overnight with anti-PRMT5 
(A1520; NeoBiolab), anti-BRD4 (A301-985A; Bethyl) or 3 μg of the negative control antibody, anti-IgG 
(Millipore). Immune complexes were collected by incubation with 20 μL magnetic protein G beads at 
4°C for 1.5 hours. Protein G-bound complexes were sequentially washed with Low Salt Wash Buffer, 
High Salt Wash Buffer, LiCl Wash Buffer and twice with TE Buffer (ChIP Assay Kit, Millipore). Elution 
of protein/DNA complexes was performed using 1% SDS and 0.1 M NaHCO3. Following reversal of 
crosslinks (65°C overnight), samples were treated with RNAse A and then Proteinase K. DNA 
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samples were purified using the QIAquick PCR purification kit (Qiagen, Hombrechtikon, Switzerland). 
Chromatin samples to which no antibody had been added were processed in parallel as input 
references. For quantitative PCR (qPCR) analysis of ChIP samples, triplicate wells containing 1 μL of 
purified ChIP DNA plus PCR master mix were prepared. Reactions were performed on a StepOnePlus 
Real-Time PCR system (Applied Biosystems). Standard curves were constructed using sonicated and 
purified chromatin. ChIP-qPCR was performed using primers specific for the upstream regulatory 
regions of PRMT5 and miR-96-5p. Primer sequences were as follows: PRMT5 forward; 5’-
AGCGCGAGGAGAAAGATG-3’, PRMT5 reverse; 5’-CTATTTCGGGGACGCAATTC-3’, miR-96 
forward; 5’-AGCTGGGAGACCTTGCTTC-3’, miR-96 reverse; 5’-TCACCCCTCCTAACCCAAAT-3’. 
 
RESULTS 
BET inhibition modulates the expression of a subset of microRNAs  
We have previously shown that the BETi OTX015 modulates the expression of multiple coding 
transcripts in DLBCL cells 15. Here, we assessed the effect of OTX015 on global miRNA expression. 
The GCB-DLBCL OCI-LY-1 and the ABC-DLBCL HBL-1 were treated with 500 nM OTX015 for 4 and 
24 hours. Total RNA isolated from vehicle- and OTX015-treated cells was interrogated with the 
Nanostring nCounter. The miRNAs modulated by the BETi were 14 (five downregulated, nine 
upregulated) in OCI-LY-1 and 11 (five downregulated, six upregulated) in HBL-1 (Table 1). 
Additionally, we used the Agilent Human microRNA microarray v.3. platform to perform miRNA 
profiling on two more DLBCL cell lines, DOHH-2 (GCB-DLBCL) and SU-DHL-2 (ABC-DLBCL), the 
same cell lines we had previously used for mRNA profiling of OTX015-treated cells 15. In this case, 
seven miRNAs (three downregulated, four upregulated) were affected by OTX015 in the GCB-DLBCL, 
and five (two downregulated, three upregulated) in the ABC-DLBCL cell line (Table 1). 
A few miRNAs were affected in more than one cell line, although we could not determine clear 
subtype-specific differences in miRNA modulation since only one GCB- and one ABC-DLBCL cell line 
were interrogated on each profiling platform. The oncogenic miR-92a-1-5p 35, belonging to the miR-17-
92 cluster, was downregulated in three of four cell lines (two ABC-DLBCL, one GCB-DLBCL). miR-
204-5p, involved in BRAF resistance in melanoma 36, was downregulated and miR-487b-3p, 
expressed at lower levels in DLBCL versus follicular lymphoma 37, was upregulated in both cell lines 
analyzed with the Nanostring platform. The tumor suppressor miR-96-5p 38, 39 was upregulated in 
HBL-1 and in DOHH-2. Besides these, among the miRNAs modulated by the BET inhibitor there were 
others known to be involved in lymphomagenesis. The oncogenic miRNAs hsa-miR-21-3p 40-44 and 
miR-155 45, 46 were downregulated, while, besides miR-96-5p,  another miRNA with a tumor 
suppressor function,  miR-16-5p 47, was also upregulated by BETi. Quantitative real-time PCR was 
used to validate the expression of two lymphoma oncomiRs modulated by BETi: miR-155-5p and miR-
92a-1-5p (Supplementary Figure S1). The latter appeared also significantly downregulated after in 
vivo treatment of SU-DHL-2 xenografts (Supplementary Figure S2). 
 
microRNAs modulated by BETi control important pathways in DLBCL 
Functional annotation analysis identified the p53 pathway, apoptosis, MYC-targets, cell cycle 
regulation, B cell receptor signalling, IL-6 signalling, STAT3 pathway, PI3K and Nf-κB signalling 
among the biological processes significantly associated with the miRNAs that exhibited expression 
changes in HBL-1 and OCI-LY-1 DLBCL cells treated with OTX015 (Supplementary Table S1). The 
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same pathways were predicted to be affected based on the modulated miRNAs in DOHH-2 and SU-
DHL-2 cells treated with OTX015 (Supplementary Table S1). These signalling pathways and 
processes were similar to those we previously observed when analysing the gene expression profiles 
of OTX015-treated DLBCL cells 15.  
 
BRD4 binds to the upstream regulatory regions of multiple miRNAs 
To further study the role of BET proteins in miRNA regulation, we took advantage of two publicly 
available ChIP-Seq datasets obtained in the ABC-DLBCL cell line HBL-1 (SRP043524) 23 and in the 
GCB-DLBCL cell line OCI-LY-1 (SRP022129) 22, both treated with the BET inhibitor JQ1 or DMSO 
alone.  Analysis of these datasets revealed that half of the regions bound by BRD4 were in intronic 
and intergenic regions where miRNAs are often located 48. We detected 794 miRNAs with at least one 
BRD4-binding event within their regulatory regions in the ABC-DLBCL HBL-1 and 757 in the GCB-
DLBCL OCI-LY-1 (Supplementary Table S2). To determine if BRD4 binding was associated with the 
expression of miRNA genes we profiled miRNA expression levels in a panel of 35 lymphoma cell lines 
using the Nanostring nCounter (Supplementary Table S3). Comparison of miRNA expression levels 
and BRD4 binding sites demonstrated that BRD4 peaks were more prevalent in the proximity of 
expressed miRNAs than non-expressed miRNAs (p-value <0.001) and were positively correlated with 
miRNA expression levels (Figure 1A). When we compared BRD4 binding in the presence or absence 
of the BETi JQ1, we identified 707 miRNAs with decreased BET bromodomain binding after exposure 
to the BETi in the ABC-DLBCL HBL-1 and 348 in the GCB-DLBCL OCI-LY-1 (Supplementary Table 
S2). Downregulation of miR-92a-1-5p and miR-155p expression following BETi-mediated reduction of 
BRD4 binding was also confirmed by qRT-PCR analysis (Figure 1B). 
 
BET inhibition mediates upregulation of miR-96-5p by downregulating PRMT5 expression 
The observed upregulation of the tumour suppressor miR-96-5p after exposure of DLBCL cell lines to 
OTX015 could not be explained by a direct BRD4-mediated effect of the BETi on the miRNA promoter. 
Thus, the miRNA profiling results were further validated by qRT-PCR in two GCB- (DOHH-2, OCI-LY-
1) and two ABC- DLBCL (SU-DHL-2, HBL-1) cell lines treated with OTX015 for 4, 24 and 48 hours. 
For DOHH-2, SU-DHL-2 and HBL-1, there was a time-dependent upregulation of miR-96-5p. For OCI-
LY-1, miR-96-5p was similarly upregulated at all three time points (Figure 2A). 
In lymphomas, miR-96-5p expression is regulated as part of a negative feedback loop with the protein 
arginine methyltransferase, PRMT5 39. Overexpression of PRMT5 mediates transcriptional repression 
of this miRNA via symmetric dimethylation of histones H3 and H4 in the promoter of miR-96-5p. 
Conversely, binding of miR-96-5p to the 3’ untranslated region of PRMT5 inhibits its translation 39, 49. 
We hypothesized that the upregulation of miR-96-5p observed in OTX015-treated DLBCL cells could 
be due to a perturbation of its downregulation by PRMT5. To assess this, we performed qRT-PCR 
analysis of PRMT5 in DLBCL cells treated with OTX015 for 4, 24 and 48 hours. PRMT5 mRNA was 
markedly downregulated at 4 and 24 hours. At 48 hours PRMT5 levels were similar in DMSO- and 
OTX015-treated cells for all four cell lines (Figure 2B). At the protein level (Figure 2C), moderate 
downregulation of PRMT5 was evident at 24 hours in DOHH-2 cells treated with OTX015. In SU-DHL-
2 cells, PRMT5 was moderately downregulated at 24 hours and was negligible at 48 hours. These 
results indicated that OTX015 could downregulate PRMT5 expression at both RNA and protein levels 
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in DLBCL cells. Hence upregulation of miR-96-5p following OTX015 treatment was associated with 
downregulation of PRMT5 protein, particularly in SU-DHL-2.  
 
BRD4 binds to the 5’ regulatory region of PRMT5 in DLBCL cells and treatment with BETi 
reduces BRD4 binding 
As OTX015 mediates transcriptional repression by displacing BRD4 from chromatin 15, 21, we 
hypothesized that PRMT5 was transcriptionally regulated by BRD4. To assess this, we analysed again 
the two public ChIP-Seq datasets of DLBCL cells treated with the BETi JQ1 22, 23, which has a similar 
mechanism of action to OTX015 and exhibits an overlapping profile of targeted genes 15, 22. This 
revealed that BRD4 bound to the 5’ region of PRMT5 and that this binding reduced following BETi 
treatment (Figure 3A). In agreement with the public ChIP-Seq data of JQ1-treated DLBCL cells, when 
we performed ChIP-qPCR analysis of SU-DHL-2 cells treated with OTX015, we observed decreased 
binding of BRD4 to the 5’ region of PRMT5 (Figure 3B). Therefore, the decrease in PRMT5 expression 
following OTX015 treatment was likely due to reduced association of BRD4 to the 5’ regulatory region 
of PRMT5. Additionally, DNAse hypersensitivity sites and H3K27 acetylation, both marks of active 
transcription, were enriched at the BRD4 binding site in PRMT5 (data not shown).  As PRMT5 and 
miR-96-5p regulate each other in a negative feedback loop, we tested for binding of PRMT5 to the 
promoter of miR-96-5p. OTX015 treatment led to reduced recruitment of PRMT5 to the miR-96-5p 
promoter (Figure 3C) indicating that upregulation of miR-96-5p in BETi-treated cells was mediated 
through downregulation of PRMT5 (Figure 3D). 
 
DISCUSSION 
The present study shows that the BETi OTX015 modulates the expression of miRNAs in DLBCL cells. 
The regulation may occur directly, due to the binding of BRD4 to the regulatory regions of specific 
miRNAs, or indirectly as demonstrated for miR-96-5p, a miRNA with important functions in the 
proliferation and survival of B-cell malignancies 49. The ability of OTX015 to alter miRNA expression 
demonstrates that the effects of BETi on the transcriptome extend beyond coding genes to comprise 
also non-coding regions of the genome. miRNAs function by regulating the expression of genes at the 
transcript level, where they can mediate mRNA degradation, reduce mRNA stability or prevent 
translation of mRNA into protein.  
By analysing publicly available ChIP-Seq data 22, 23 in combination with our miRNA profiling data of 
baseline and BETi-treated lymphoma cells, we determined that a subset of miRNAs were bound by 
BRD4 and that this binding decreased after BETi treatment. For a number of these miRNAs reduced 
binding of BRD4 after BETi was associated with reduced expression. Our finding that BRD4 directly 
binds to the regulatory regions of miRNA genes to regulate their expression in lymphomas 
complements the recent report describing that components of miRNA processing machinery, namely 
DGCR8 and Drosha, are localised to super-enhancers of miRNAs in a tissue-specific manner and that 
association of these proteins with super-enhancers is reduced following treatment with the BETi JQ1 
50
. Indeed, these observations indicate that the targeted effects of BETi on specific genes in different 
cellular contexts also likely comprises non-coding transcripts that are specifically modulated in 
different transformed cell types. With respect to this, we observed that the promoters of two 
established lymphoma oncomiRs, miR-155-5p and miR-92a-1-5p, were bound by BRD4. When 
lymphoma cells were treated with BETi, BRD4 was diminished at these sites and this was associated 
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with downregulation of miRNA expression. miR-155-5p is upregulated in activated B-cells and ABC-
DLBCL 45, 46, 51, often because of amplification of its locus 45. Its high expression is associated with 
poor outcome and resistance to R-CHOP therapy and its knockdown compromises the viability of 
ABC-DLBCL cells 43, 45. Of interest, BETi treatment decreased miR-155-5p expression only in the two 
ABC-DLBCL cell lines, while the GCB-DLBCL cell line showed upregulation of miR-155-5p suggesting 
that different mechanisms may regulate the transcription of this miRNA gene in different DLBCL 
subtypes. miR-92a-1-5p is one of the six members of the miR-17-92 cluster located on chromosome 
13q31.3 and is overexpressed in different lymphoma subtypes including DLBCL 35. It is a 
transcriptional target of the MYC oncoprotein 35, which is itself rapidly and robustly downregulated by 
BETi treatment 15. Downregulation of miR-92a-1-5p was already very pronounced after 4 hours of 
BETi treatment. Additionally, miR-92a-1-5p was the only miRNA commonly identified by the two 
different platforms that we utilized for miRNA profiling. The miR-17-92 cluster is involved in the 
activation of the PI3K/AKT/mTOR pathway, lymphoma pathogenesis and chemoresistance 52, 53. The 
miR-17-92 cluster can acquire super-enhancers during neoplastic transformation 50, 54 and BRD4 
exhibits a preference for binding at super-enhancers 22. This provides further support for our 
observation of direct regulation of the miR-17-92 cluster by BRD4.  
miR-21-3p was also downregulated by BETi treatment. This miRNA is overexpressed in B-cell 
lymphomas 40-42. It inhibits translation of the tumour suppressor PTEN 43 and knockdown of miR-21 
increases the sensitivity of lymphoma cells to CHOP 44. 
When we performed functional annotation analysis of the OTX015-modulated miRNAs, we identified 
the same signalling pathways and processes that we had previously identified from gene expression 
profiles of OTX015-treated DLBCL cells 15, indicating that changes in miRNA expression likely 
contribute to modulating some of the transcripts and pathways that have been previously identified in 
BETi-treated cells 15, 22, 23. 
In lymphoma cells, which overexpress PRMT5, the negative feedback loop comprising miR-96-5p and 
PRMT5 is usually poised in favour of PRMT5 39. PRMT5 catalyses the symmetric methylation of 
arginine residues on histones H3 and H4, giving rise to the repressive epigenetic marks H3R8me2S 
and H4R3me2S. Inhibition of PRMT5 expression pharmacologically or by the use of antisense 
oligonucleotides, severely compromises lymphoma cell viability and induces apoptosis 39, 49. In the 
DLBCL cells we treated with OTX015, PRMT5 protein was negligible after 48 hours of treatment in the 
ABC-DLBCL cell line SU-DHL-2, which we have previously shown to undergo pronounced apoptosis 
in response to OTX015 15. DOHH-2 cells, in which we did not observe apoptosis following OTX015 
treatment 15, exhibited moderate PRMT5 downregulation. The less marked downregulation of PRMT5 
protein in DOHH-2 cells treated with OTX015 was in contrast to its pronounced downregulation at the 
transcript level. It was nevertheless associated with a pronounced increase in miR-96-5p levels 
indicating that for this cell line, factors other than PRMT5 downregulation may contribute to releasing 
miR-96-5p from transcriptional repression. Inhibition of PRMT5 has been shown to release miR-96-5p 
from transcriptional repression in lymphoma cells 39. We observed that BETi-mediated inhibition of 
PRMT5 was associated with decreased binding of BRD4 to the 5’ regulatory region of PRMT5 and 
that this resulted in reduced occupancy of PRMT5 at the miR-96-5p promoter. The disruption of the 
negative feedback loop comprising PRMT5 and miR-96-5p by OTX015 shows how the anti-tumour 
effects of BETi are further amplified by modulation of secondary targets, which might themselves also 
contribute to further suppress direct targets of BETi. With respect to this, overexpression of miR-96-5p 
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downregulates phosphorylated STAT3 (p-STAT3) without affecting levels of total STAT3 in T-cell 
anaplastic large-cell lymphoma cells (ALCL) 38. We have previously shown that OTX015 treatment 
decreases p-STAT3 in ABC-DLBCL cells 15. It is therefore possible that in addition to the direct effects 
of OTX015 on the expression of genes involved in JAK/STAT signalling 15, the overexpression of miR-
96-5p contributes to maintaining p-STAT3 repressed.  
Our study provides the first evidence of BETi modulation of miRNAs in lymphomas. This modulation 
can occur by inhibiting the interaction of BRD4 with genes whose products regulate miRNA 
expression, or through the direct inhibition of BRD4 at miRNA regulatory regions, or, as recently 
suggested, by interfering with the processing of pri-miRNA to pre-miRNAs 50. Unlike coding 
transcripts, miRNAs are highly stable in blood and as such, levels of circulating miRNAs have been 
used for diagnosis and screening in a number of diseases. In lymphomas, the overexpression of 
specific miRNAs in plasma and serum samples has been shown to be an accurate biomarker for 
diagnosis, prognosis and response to therapy 45. The circulating miRNAs that have been identified as 
biomarkers in lymphoma are among those that we have identified as regulated by BETi (miR-92, miR-
21, miR-155). Therefore, assessment of circulating miRNAs could be used as a robust and non-
invasive way to monitor response to BETi treatment. 
In conclusion, our observations contribute to a better understanding of the targeted effects of BETi, 
revealing a novel aspect of the activity of this class of compounds in lymphomas. 
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Table 1. miRNAs modulated by the BETi OTX015 in four DLBCL cell lines. 
 
 
OCI-LY-1 (GCB-DLBCL) 
 4 hours 24 hours 
microRNA_ID log2FC p-value log2FC p-value 
hsa-miR-639 -1.38 0.005 -0.29 n.s. 
hsa-miR-204-5p ^ -0.46 n.s. -1.61 0.048 
hsa-miR-6511a-5p -0.43 n.s. -1.38 0.034 
hsa-miR-106a-5p+hsa-miR-17-5p -0.33 n.s. -0.95 0.035 
hsa-miR-3613-5p 0.30 n.s. -3.30 <0.001 
hsa-miR-1254 0.96 0.031 0.73 n.s. 
hsa-miR-760 1.07 0.012 0.84 n.s. 
hsa-miR-221-5p 1.46 0.004 -0.07 n.s. 
hsa-miR-498 1.84 0.013 -0.48 n.s. 
hsa-miR-487b-3p ^ -0.02 n.s. 1.58 0.016 
hsa-miR-16-5p 0.07 n.s. 1.22 0.012 
hsa-miR-182-5p 0.24 n.s. 0.95 0.025 
hsa-miR-3136-5p 0.43 n.s. 1.51 0.013 
hsa-miR-3605-3p 0.48 n.s. 1.47 0.014 
     
 
HBL-1 (ABC-DLBCL) 
 4 hours 24 hours 
microRNA_ID log2FC p-value log2FC p-value 
hsa-miR-204-5p ^ -1.59 0.011 -0.58 n.s. 
hsa-miR-133a-5p -1.13 0.020 0.26 n.s. 
hsa-miR-155-5p -0.67 n.s. -1.11 0.017 
hsa-miR-580-3p -0.22 n.s. -1.11 0.017 
hsa-miR-92a-1-5p ^ -0.45 n.s. -1.93 0.009 
hsa-miR-487b-3p ^ 1.59 0.007 -0.32 n.s. 
hsa-miR-652-5p 2.08 <0.001 0.56 n.s. 
hsa-miR-191-5p 0.16 n.s. 1.17 0.007 
hsa-miR-96-5p ^ 0.41 n.s. 0.99 0.023 
hsa-miR-433-3p 0.49 n.s. 1.75 0.014 
hsa-miR-582-3p 0.72 0.059 1.88 0.001 
     
 
DOHH2 (GCB-DLBCL) 
 
4 hours 8 hours 
microRNA_ID log2FC p-value log2FC p-value 
hsa-miR-196a-3p -0.44 0.039 0.29 n.s. 
hsa-miR-21-3p -0.37 0.045 -0.48 n.s. 
hsa-miR-92a-1-5p ^ -0.32 n.s. -0.52 0.0177 
hsa-miR-630 0.63 0.036 -0.33 n.s. 
hsa-miR-935 0.36 0.049 1.45 n.s. 
hsa-miR-1181 0.07 n.s. 0.61 0.0086 
hsa-miR-96-5p ^ 0.01 n.s. 0.39 0.0415 
     
 
SU-DHL-2 (ABC-DLBCL) 
 
4 hours 8 hours 
microRNA_ID log2FC p-value log2FC p-value 
hsa-miR-92a-1-5p ^ -0.78 0.004 -2.01 0.004 
hsa-miR-29b-1-5p -0.25 n.s. -0.46 0.043 
hsa-miR-765 0.39 0.102 0.48 0.011 
hsa-miR-1246 0.23 n.s. 0.64 0.025 
hsa-miR-345-5p 0.13 n.s. 0.58 0.015 
 
^, modulated in more than one cell line; n.s., not significant. 
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Figure legends 
  
Figure 1. BRD4 binds to the regulatory regions of miRNAs. A) The genomic regions within ± 1 kb 
of microRNA promoters that are bound by BRD4 obtained using ngs.plot. Lines represent the average 
expression profiles of “Expressed” (red line) and “Not Expressed” (green line) miRNA. B) Analysis of 
publicly available ChIP-Seq data of DLBCL cells showed that BETi treatment reduces BRD4 binding at 
the 5’ regulatory regions of the miR-17-92 cluster, which contains miR-92a-1-5p, and the miR-155 host 
gene (left panel). An ABC-DLBCL cell line (SU-DHL-2) and a GCB-DLBCL cell line (DOHH-2) were 
treated with OTX015 for 4 and 24 hours before TaqMan qRT-PCR analysis of miR-92a-1-5p and miR-
155-5p expression (right panel). miR-155-5p expression is only shown for SU-DHL-2 as it is an ABC-
DLBCL specific oncomiR. Expression of RNU6B was used for normalisation. For each timepoint, the 
mean fold change relative to the DMSO control is shown. Charts show the mean of at least three 
independent experiments. *, p < 0.05; **, p < 0.01. Error bars denote the SE. 
 
Figure 2. OTX015 modulates miR-96-5p expression in DLBCL models. A) OTX015 upregulates 
miR-96-5p in a time-dependent manner. Two GCB-DLBCL (DOHH-2, OCI-LY-1) and two ABC-DLBCL 
(SU-DHL-2, HBL-1) cell lines were treated with DMSO or 500 nM OTX015 for 4, 24, and 48 hours. 
Expression of miR-96-5p was determined by TaqMan qRT-PCR. Expression of RNU6B was used for 
normalisation. For each timepoint, the mean fold change relative to the DMSO control is shown. B) 
OTX015 treatment of DLBCL cells downregulates PRMT5. Two GCB-DLBCL (DOHH-2, OCI-LY-1) 
and two ABC-DLBCL (SU-DHL-2, HBL-1) cell lines were treated with DMSO or 500 nM OTX015 for 4, 
24, and 48 hours. Expression of PRMT5 was determined by qRT-PCR. GAPDH expression was used 
for normalisation. For each timepoint, the mean fold change relative to the DMSO control is shown. C) 
OTX015 reduces PRMT5 protein levels in DOHH-2 and SU-DHL-2 cells treated with DMSO or 500 nM 
OTX015. GAPDH was used as a loading control. PRMT5 signals were quantified using ImageJ 
(http://rsbweb.nih.gov/ij/) and normalized to GAPDH signals. Representative images of two 
independent Western blot analyses are shown. Charts show the mean of three independent 
experiments. **, p < 0.01. Error bars denote the SE. 
 
Figure 3. OTX015 reduces binding of BRD4 to PRMT5 and diminishes recruitment of PRMT5 to 
the miR-96-5p promoter. A) Analysis of publicly available ChIP-Seq data of DLBCL cells treated with 
the BETi JQ1 showed that BRD4 binds to the 5’ regulatory region of PRMT5 and that BETi treatment 
reduces BRD4 recruitment to PRMT5. B-C) ChIP was performed for DLBCL cells treated with DMSO 
or 500 nM OTX015 for 48 hours. Anti-BRD4, anti-PRMT5 and anti-IgG (negative control) antibodies 
were used for immunoprecipitations. B) Chromatin pulled down with anti-BRD4 and anti-IgG in DMSO- 
and OTX015-treated SU-DHL-2 cells was amplified with primers specific for the 5’ regulatory region of 
PRMT5 identified by the analysis in (A). C) Chromatin pulled down with anti-PRMT5 and anti-IgG 
antibodies in DMSO- and OTX015-treated HBL-1 cells was amplified with primers specific for the 
promoter of miR-96-5p. Amplification of the same immunoprecipitated chromatin samples was 
performed with primers specific for the chromosome 4 human alpha satellite sequence as an 
additional negative control (representative results from one of two biological replicates shown). Charts 
show the mean fold difference between DMSO- and OTX015-treated cells after normalisation to Input 
and IgG background subtraction. ChIP-qPCR experiments were repeated twice in triplicates. D) 
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Proposed model for the upregulation of miR-96-5p expression following treatment of DLBCL cells with 
OTX015. Upper panel; previous work by others has shown that PRMT5 is overexpressed in lymphoma 
cells where it mediates transcriptional repression of miR-96 and that overexpression of miR-96 
negatively regulates PRMT5 translation 39, 49. Lower panel; here we showed that BRD4 binds to the 
upstream regulatory region of PRMT5. Treatment of DLBCL cells with BETi reduced BRD4 occupancy 
at the PRMT5 locus and also reduced the expression of PRMT5 mRNA and protein. Additionally, BETi 
diminished the occupancy of PRMT5 at the miR-96 promoter and increased miR-96 expression. **, p 
< 0.01. Error bars denote the SE. 



 Supplementary Data 
 
Supplementary Figure 1 
OTX015 modulates miRNA expression in an in vivo DLBCL model. miR-92a-1-5p expression was 
assessed in SU-DHL-2 xenografts from NOD-SCID mice previously treated with vehicle (control) or 
OTX015 for three days 1. The thick black line in each boxplot denotes the median expression. 
Expression of RNU6B was used for normalisation. 
 
 
Supplementary Tables Legends 
 
Supplementary Table S1. Canonical pathways and hallmarks associated with OTX015-modulated 
miRNAs.  
 
Supplementary Table S2. miRNAs with at least one BRD4-binding event within their regulatory regions 
and miRNAs with decreased BRD4-binding after exposure to JQ1, as determined via data mining of the 
ChIP-Seq datasets obtained in the ABC-DLBCL cell line HBL-1 (SRP043524) 2 and in the GCB-DLBCL 
cell line OCI-LY-1 (SRP022129) 3. 
 
Supplementary Table S3. Names and histological derivation of cell lines used for baseline miRNA 
profiling. Cell lines have already been used and described in previous studies 4, 5.  
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